An α-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients

Kazuo Eguchi, Takahiro Komori, Toshinobu Saito, Satoshi Hoshide, Kazuomi Kario

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


Background We tested the hypothesis that an alpha-glucosidase inhibitor (α-GI), miglitol, is effective in protecting the cardiovascular system in type 2 diabetes mellitus (T2DM). Methods We studied 19 hospitalized heart disease patients with T2DM in whom we performed continuous glucose monitoring, Holter electrocardiogram, and ambulatory blood pressure (BP) monitoring simultaneously for 48 h. The α-GI miglitol was administered for half of the study period by a cross-over fashion. T-wave alternans (TWA), a marker of future fatal arrhythmic events, was also analyzed by Holter ECG. Results Of the 19 patients, the measures of glucose variability were significantly lower during miglitol therapy than in control period. BP variability was similar with/without miglitol. However, TWA was significantly lower during the miglitol period compared to control period (63 ± 4.8 vs. 75.8 ± 5.1 μV, p = 0.032). Conclusion An α-GI, miglitol, can reduce TWA by reducing the fluctuation of glucose in heart disease patients with T2DM.

Original languageEnglish
Pages (from-to)21-26
Number of pages6
JournalJournal of Electrocardiology
Issue number1
StatePublished - Jan 2018
Externally publishedYes


  • Alpha-glucosidase inhibitor
  • Glycemic variability
  • T-wave alternans


Dive into the research topics of 'An α-glucosidase inhibitor could reduce T-wave alternans in type 2 diabetes patients'. Together they form a unique fingerprint.

Cite this